Advertisement

Quanterix, a diagnostics startup in Cambridge, MA, has developed a highly sensitive new technology capable of detecting a single, cancer-linked molecule in blood, to predict the recurrence of prostate cancer. In a new study of 30 men who had their prostates removed, the test could detect low levels of the molecule that commercial assays missed.

SOURCE

Advertisement
Advertisement